|
| 胸腔镜术后肺腺癌患者的无瘤生存分析 |
| Analysis of disease-free survival with lung adenocarcinoma undergoing thoracoscopic surgery |
| 投稿时间：2020-12-31 |
| DOI：10.3969/j.issn.1000-0399.2021.06.004 |
| 中文关键词: 肺腺癌 胸腔镜 无瘤生存期 生存分析 预后 |
| 英文关键词: Lung adenocarcinoma Thoracoscopy Disease-free survival Survival analysis Prognosis |
| 基金项目:中央转移支付财政建设项目（项目编号：Z155080000004） |
|
| 摘要点击次数: 1438 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探讨胸腔镜手术治疗后肺腺癌患者的无瘤生存情况及其影响因素方法 回顾性分析2015年7月至2017年1月安徽省胸科医院122例胸腔镜手术肺腺癌患者的临床资料，运用Kaplan-Meier法计算无瘤生存率，对影响患者术后无瘤生存的影响因素使用log-rank检验及Cox回归方法进行单因素及多因素分析结果 122例胸腔镜治疗肺腺癌患者出院后随访36~54个月，中位随访时间41个月，平均无瘤生存时间45.57（95% CI：42.938~48.193）个月，总体1、2及3年无瘤生存率分别为94.26%、85.25%和78.69%。Cox多因素回归分析显示，年龄≥60岁、病理分期为ⅡB期、ⅢA期、Ⅳ期，淋巴结转移，病灶>3 cm是影响肺腺癌患者术后无瘤生存的危险因素（P<0.05）结论 年龄、TNM分期、淋巴结转移、病灶大小是行胸腔镜手术治疗肺腺癌患者无瘤生存的影响因素。 |
| 英文摘要: |
| Objective To investigate the disease-free survival of patients with lung adenocarcinoma after thoracoscopic surgery and its influencing factors. Methods The clinical data of 122 patients with lung adenocarcinoma undergoing thoracoscopic surgery were analyzed by regression analysis. Kaplan Meier method was used to draw the disease-free survival curve of patients with lung adenocarcinoma after thoracoscopic surgery, and the disease-free survival rate was calculated. The influencing factors of disease-free survival were analyzed by log rank test and Cox regression. Results A total of 122 patients were followed up for 36~54 months after discharge. The median follow-up time was 41 months. The average disease-free survival time was 45.57(95%CI:42.938~48.193) months.The 1-year,2-year and 3-year disease-free survival rates was 94.26%,85.25% and 78.69% respectively. Cox multivariate regression analysis showed that age ≥ 60 years, pathological stage of stage IIB, stage IIA and stage IV, lymph node metastasis, and lesions >3 cm were independent risk factors for tumor free survival of patients with lung adenocarcinoma (P<0.05). Conclusion Age, TNM stage, lymph node metastasis and lesion size are the influencing factors of tumor free survival in patients with lung adenocarcinoma after VATS. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
